Table 3.

Effects of different CYP inhibitor treatments on the sterol profile of LV82 promastigotes

Sterol Group	Sterol name	20 μM clotrimazole vs. DMSO	50 μM voriconazole vs. DMSO
4- and/or 14-methylated sterols	Lanosterol	2.7 ± 0.9**	1.6 ± 0.2
	4CH2OH-LS	2.3 ± 0.5	0.83 ± 0.09
	4,14-Dimethylzymosterol	43 ± 18***	17 ± 2**
	14-Methylzymosterol	2.3 ± 0.4**	8.0 ± 1.0**
	14-Methylfecosterol	Accumulateda,***	Accumulateda,***
	4-Methylzymosterolb	0.025 ± 0.013***	0.18 ± 0.06**
	FF-MAS	Not detected	Not detected
	T-MAS	Not detected	Not detected
4,14-demethylated sterols	Zymosterolc	0.018 ± 0.006**	0.067 ± 0.034**
	Fecosterolb	0.025 ± 0.013***	0.18 ± 0.06**
	Episterolb	0.025 ± 0.013***	0.18 ± 0.06**
	Cholesta-7,24-dienolc	0.018 ± 0.006**	0.062 ± 0.030**
5-dehydro sterols	7-Dehydrodesmosterol	0d,**	0d,**
	5-Dehydroepisterol	0.20 ± 0.04**	0.078 ± 0.043***
	Ergosta-5,7-dienol	0.79 ± 0.26	0.39 ± 0.11**
	Ergostatetraenol	0 d,**	0.086 ± 0.027**
	Ergosterol	0.26 ± 0.07**	0.30 ± 0.08***
Exogenous	Cholesterol	1.1 ± 0.2	0.88 ± 0.07

The sterol levels in inhibitor-treated parasites were normalized to the corresponding sterol levels in DMSO-treated parasites. The values represent mean ± standard deviation. Each ratio is an average of three individual experiments conducted on separate days. Each experiment had biological triplicates. Source data are provided as a Source Data file.

^aThis sterol was detected in inhibitor-treated samples but not in vehicle-treated samples

^bEpisterol, fecosterol and 4-methylzymosterol could not be chromatographically separated.

^cZymosterol and Cholesta-7,24-dienol could not be chromatographically separated.

^dThis sterol was detected in vehicle-treated samples but not in inhibitor-treated samples.

**, *** unpaired two-tailed t-test (**P < 0.01; ***P < 0.001).